Embrex

Embrex is a pioneer in poultry biotechnology, best known for developing the Inovoject system, the first commercially viable in-ovo (in-the-egg) injection technology. This system automates the vaccination of chick embryos, significantly improving efficiency and bird health compared to post-hatch methods. The company's portfolio includes a range of biological products and vaccines targeting major avian diseases such as Marek's disease and coccidiosis. Acquired by Pfizer in 2006, Embrex's technologies now form a core part of Zoetis's poultry health division. The company's focus remains on enhancing global food production through advanced veterinary diagnostics and automated delivery systems.